You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Guidelines and Advice
Status: Current
ID: PET 13
Jan 2015
Guidelines and Advice
Status: Current
ID: 15-12
Version: 2
Jan 2015
Drug
Other Name(s): Vesanoid®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Thalomid®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Lanvis®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
thalidomide (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
talimogene laherparepvec (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tamoxifen,
ribociclib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
triptorelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Guidelines and Advice
Status: In-Review
ID: GL 6-A-2018-1
Mar 2019